Macrophage EP4 Loss Accelerates Atherosclerosis
2026-09-05
The reference study identifies macrophage EP4 as a protective regulator of atherosclerosis and links its loss to increased CD36 expression, lipid uptake, foam-cell formation, and M1 polarization. By combining a myeloid-specific knockout model with oxLDL-stimulated cells, transcriptomics, proteomics, and molecular validation, the work provides a mechanistic framework for interpreting EP4 signaling in plaque progression.
Plerixafor (AMD3100): CXCR4 Research Guide
2026-09-05
Plerixafor, also called AMD3100, is a small-molecule CXCR4 antagonist that disrupts CXCL12 signaling. Its strongest established research uses are hematopoietic stem cell mobilization, CXCR4-axis experiments, and mechanistic studies of cancer metastasis and inflammation.
TDP-43 Aggregation: Oligomerization and RNA Binding
2026-09-04
This study shows that disrupting TDP-43 oligomerization and disrupting its RNA-binding activity do not produce the same pathological state. By combining structure-based variants, neuronal and cellular models, and proteasome-impairment experiments, the authors distinguish nuclear LLPS-driven aggregation from cytoplasmic aggresome-dependent inclusion formation.
Penicillin G Sodium: Assay Controls and Cell-Wall Biology
2026-09-04
Penicillin G Sodium is a natural penicillin antibiotic whose value extends beyond antimicrobial activity: it can also serve as a carefully bounded perturbation in infection and cell-based research. This guide connects bacterial cell-wall biology with orthogonal assay design, helping researchers distinguish antimicrobial effects from host-cell cytotoxicity and experimental artifacts.
Erastin Assays: From Redox Stress to Ferroptosis
2026-09-03
Erastin is a ferroptosis inducer that connects cystine withdrawal, glutathione loss, and lipid peroxidation in tumor models. This guide goes beyond compound description to show how mechanistic controls and orthogonal readouts improve ferroptosis research and oxidative stress assay design.
GSK621: Mechanism, AML Research, and AMPK
2026-09-03
GSK621 is a potent AMPK agonist for experimentally activating AMPK signaling, autophagy, metabolic reprogramming, and apoptosis-associated responses. Product and preclinical evidence supports its use in acute myeloid leukemia research, but AML xenograft dosing should not be interpreted as a clinical regimen.
PDHA1 Succinylation and α-KGA in Cholangiocarcinoma
2026-09-02
The reference study identifies PDHA1 lysine 83 succinylation as a metabolic switch that increases α-ketoglutarate accumulation in the cholangiocarcinoma microenvironment. The resulting OXGR1–MAPK signal suppresses macrophage MHC-II antigen presentation, while pharmacological inhibition of this axis improves the response to gemcitabine and cisplatin in experimental models.
Sulfasalazine for Sarcopenia: Mouse and Clinical Insights
2026-09-02
A 2025 study combined a PHF20–YY1 transcriptional assay, mouse muscle-atrophy models, and clinical IBD data to investigate sulfasalazine as a repurposing candidate for sarcopenia. The findings connect inhibition of YY1-associated transcriptional activity with improved myogenic markers, muscle performance, and higher psoas-based muscle indices, while also highlighting the need for controlled translational studies.
Tetracycline Hydrochloride: Applied Assay Workflows
2026-09-01
Tetracycline Hydrochloride supports controlled studies of bacterial translation, Staphylococcus aureus susceptibility, and skin microbiome modulation. This guide combines practical antimicrobial workflows with a carefully bounded comparison to rapid ROS-based cancer-cell assays, helping researchers select informative controls, time points, and troubleshooting steps.
Mithramycin A: Mechanism and Research Use
2026-09-01
Mithramycin A is an anticancer antibiotic that binds G-C-rich DNA in the presence of divalent metal ions. Its reported effects on RNA and DNA polymerases, c-myc expression, and HL-60 differentiation make it a focused tool for cancer biology research rather than a clinical treatment.
WEHI-539: Reliable BCL-XL Apoptosis Assays
2026-08-31
This scenario-driven guide explains how WEHI-539 (SKU A3935) can clarify BCL-XL-dependent apoptosis in viability, proliferation, and cytotoxicity workflows. It covers model selection, formulation constraints, orthogonal readouts, interpretation, and practical vendor evaluation using product data and published evidence.
PRINT and Safe-Harbor Transgene Insertion
2026-08-30
The reference study introduces PRINT, an RNA-only strategy that uses avian R2 retroelement proteins to insert transgenes into a multicopy human safe-harbor locus through target-primed reverse transcription. Its combination of site-directed integration, donor-DNA avoidance, and clinically relevant activity in primary human cells provides a mechanistically distinct alternative to double-strand-break repair and viral delivery, while leaving important questions about cargo range, locus scope, and long-term genomic behavior.
Y-27632 Workflow for ROCK Signaling Studies
2026-08-29
Y-27632 provides reversible ROCK1 and ROCK2 inhibition for resolving cytoskeletal phenotypes without treating the cytoskeleton as a nonspecific target. This workflow connects stress-fiber imaging, epithelial barrier experiments, and mucus-interface models with practical dosing, controls, and troubleshooting guidance.
CB-5083: Turning p97 Stress into Strategy
2026-08-29
A translational perspective on CB-5083, linking selective p97 inhibition with protein homeostasis disruption, ER biology, oncology model selection, and pharmacodynamic strategy.
Angiotensin 1/2 (1-6) in RAS Research
2026-08-28
Use Angiotensin 1/2 (1-6) as a defined hexapeptide input for vascular, renal, and receptor-binding experiments. Its controlled composition supports cleaner dose-response studies, while recent spike–receptor findings create a carefully bounded extension into host–virus biochemistry.
459 records 6/31 page Previous Next First page 上5页 678910 下5页 Last page